Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 251


Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study.

Bühler S, Jaeger VK, Adler S, Bannert B, Brümmerhoff C, Ciurea A, Distler O, Franz J, Gabay C, Hagenbuch N, Herzog C, Hasler P, Kling K, Kyburz D, Müller R, Nissen MJ, Siegrist CA, Villiger PM, Walker UA, Hatz C.

Rheumatology (Oxford). 2019 Mar 15. pii: kez045. doi: 10.1093/rheumatology/kez045. [Epub ahead of print]


Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.

Blanchard Rohner G, Chatzis O, Chinwangso P, Rohr M, Grillet S, Salomon C, Lemaître B, Boonrak P, Lawpoolsri S, Clutterbuck E, Poredi IK, Wijagkanalan W, Spiegel J, Pham HT, Viviani S, Siegrist CA.

Clin Infect Dis. 2018 Jul 26. doi: 10.1093/cid/ciy594. [Epub ahead of print]


Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Huttner A, Siegrist CA.

Expert Rev Vaccines. 2018 Dec;17(12):1105-1110. doi: 10.1080/14760584.2018.1546582. Epub 2018 Nov 15. Review.


Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation.

Pittet LF, Verolet CM, McLin VA, Wildhaber BE, Rodriguez M, Cherpillod P, Kaiser L, Siegrist CA, Posfay-Barbe KM.

Am J Transplant. 2019 Mar;19(3):844-854. doi: 10.1111/ajt.15101. Epub 2018 Oct 1.


Usefulness of a systematic approach at listing for vaccine prevention in solid organ transplant candidates.

Blanchard-Rohner G, Enriquez N, Lemaître B, Cadau G, Combescure C, Giostra E, Hadaya K, Meyer P, Gasche-Soccal PM, Berney T, van Delden C, Siegrist CA.

Am J Transplant. 2019 Feb;19(2):512-521. doi: 10.1111/ajt.15097. Epub 2018 Oct 12.


Hepatitis B prevalence, risk factors, infection awareness and disease knowledge among inmates: a cross-sectional study in Switzerland's largest pre-trial prison.

Gétaz L, Casillas A, Siegrist CA, Chappuis F, Togni G, Tran NT, Baggio S, Negro F, Gaspoz JM, Wolff H.

J Glob Health. 2018 Dec;8(2):020407. doi: 10.7189/jogh-08-020407.


Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein 180L Single-Nucleotide Polymorphism Is Associated With Susceptibility to Recurrent Pneumococcal Lower Respiratory Tract Infections in Children.

Siebert JN, Hamann L, Verolet CM, Gameiro C, Grillet S, Siegrist CA, Posfay-Barbe KM.

Front Immunol. 2018 Aug 7;9:1780. doi: 10.3389/fimmu.2018.01780. eCollection 2018.


Correlates of vaccine-induced protective immunity against Ebola virus disease.

Medaglini D, Santoro F, Siegrist CA.

Semin Immunol. 2018 Oct;39:65-72. doi: 10.1016/j.smim.2018.07.003. Epub 2018 Jul 21. Review.


Immune system correlates of extensive limb swelling in response to conjugated pneumococcal vaccination.

Recher M, Hirsiger JR, Bigler MB, Iff M, Lemaître B, Scherer K, Häusermann P, Siegrist CA, Berger CT.

NPJ Vaccines. 2018 May 18;3:17. doi: 10.1038/s41541-018-0059-3. eCollection 2018.


[Prevention of influenza in acute care settings : a multimodal intervention].

Iten A, Bonfillon C, Siegrist CA, Kaiser L, Pittet D.

Rev Med Suisse. 2018 Apr 11;14(602):800-805. French.


Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.

Huttner A, Agnandji ST, Combescure C, Fernandes JF, Bache EB, Kabwende L, Ndungu FM, Brosnahan J, Monath TP, Lemaître B, Grillet S, Botto M, Engler O, Portmann J, Siegrist D, Bejon P, Silvera P, Kremsner P, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia.

Lancet Infect Dis. 2018 Jul;18(7):738-748. doi: 10.1016/S1473-3099(18)30165-8. Epub 2018 Apr 5.


Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan.

Vono M, Eberhardt CS, Mohr E, Auderset F, Christensen D, Schmolke M, Coler R, Meinke A, Andersen P, Lambert PH, Mastelic-Gavillet B, Siegrist CA.

Front Immunol. 2018 Feb 28;9:381. doi: 10.3389/fimmu.2018.00381. eCollection 2018.


AS03- and MF59-Adjuvanted Influenza Vaccines in Children.

Wilkins AL, Kazmin D, Napolitani G, Clutterbuck EA, Pulendran B, Siegrist CA, Pollard AJ.

Front Immunol. 2017 Dec 13;8:1760. doi: 10.3389/fimmu.2017.01760. eCollection 2017. Review.


Antenatal vaccination to decrease pertussis in infants: safety, effectiveness, timing, and implementation.

Lumbreras Areta M, Eberhardt CS, Siegrist CA, Martinez de Tejada B.

J Matern Fetal Neonatal Med. 2019 May;32(9):1541-1546. doi: 10.1080/14767058.2017.1406475. Epub 2017 Dec 3. Review.


Cautious Interpretation of Optimal Timing of Maternal Pertussis Immunization.

Eberhardt CS, Combescure C, Siegrist CA.

Clin Infect Dis. 2017 Oct 30;65(10):1766. doi: 10.1093/cid/cix536. No abstract available.


Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.

Medaglini D, Siegrist CA.

Curr Opin Virol. 2017 Apr;23:88-94. doi: 10.1016/j.coviro.2017.03.008. Epub 2017 Apr 28. Review.


A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.

Huttner A, Combescure C, Grillet S, Haks MC, Quinten E, Modoux C, Agnandji ST, Brosnahan J, Dayer JA, Harandi AM, Kaiser L, Medaglini D, Monath T; VEBCON and VSV-EBOVAC Consortia, Roux-Lombard P, Kremsner PG, Ottenhoff TH, Siegrist CA.

Sci Transl Med. 2017 Apr 12;9(385). pii: eaaj1701. doi: 10.1126/scitranslmed.aaj1701.


Pertussis Antibody Transfer to Preterm Neonates After Second- Versus Third-Trimester Maternal Immunization.

Eberhardt CS, Blanchard-Rohner G, Lemaître B, Combescure C, Othenin-Girard V, Chilin A, Petre J, Martinez de Tejada B, Siegrist CA.

Clin Infect Dis. 2017 Apr 15;64(8):1129-1132. doi: 10.1093/cid/cix046.


What Is Wrong with Pertussis Vaccine Immunity? Inducing and Recalling Vaccine-Specific Immunity.

Eberhardt CS, Siegrist CA.

Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12). pii: a029629. doi: 10.1101/cshperspect.a029629. Review.


Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous survey.

Dayer JA, Siegrist CA, Huttner A.

PLoS One. 2017 Mar 8;12(3):e0173148. doi: 10.1371/journal.pone.0173148. eCollection 2017.

Supplemental Content

Loading ...
Support Center